GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » EV-to-FCF

HLB Therapeutics Co (XKRX:115450) EV-to-FCF : -282.83 (As of May. 13, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HLB Therapeutics Co's Enterprise Value is ₩688,039 Mil. HLB Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-2,433 Mil. Therefore, HLB Therapeutics Co's EV-to-FCF for today is -282.83.

The historical rank and industry rank for HLB Therapeutics Co's EV-to-FCF or its related term are showing as below:

XKRX:115450' s EV-to-FCF Range Over the Past 10 Years
Min: -373.88   Med: -27.05   Max: 218.61
Current: -282.83

During the past 13 years, the highest EV-to-FCF of HLB Therapeutics Co was 218.61. The lowest was -373.88. And the median was -27.05.

XKRX:115450's EV-to-FCF is ranked worse than
100% of 389 companies
in the Biotechnology industry
Industry Median: 6.49 vs XKRX:115450: -282.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), HLB Therapeutics Co's stock price is ₩9340.00. HLB Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-45.169. Therefore, HLB Therapeutics Co's PE Ratio for today is At Loss.


HLB Therapeutics Co EV-to-FCF Historical Data

The historical data trend for HLB Therapeutics Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co EV-to-FCF Chart

HLB Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.30 -39.22 -26.38 -24.61 -131.52

HLB Therapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.61 201.75 -22.44 -11.01 -131.52

Competitive Comparison of HLB Therapeutics Co's EV-to-FCF

For the Biotechnology subindustry, HLB Therapeutics Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's EV-to-FCF falls into.



HLB Therapeutics Co EV-to-FCF Calculation

HLB Therapeutics Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=688038.648/-2432.716
=-282.83

HLB Therapeutics Co's current Enterprise Value is ₩688,039 Mil.
HLB Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-2,433 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLB Therapeutics Co  (XKRX:115450) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

HLB Therapeutics Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9340.00/-45.169
=At Loss

HLB Therapeutics Co's share price for today is ₩9340.00.
HLB Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-45.169.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


HLB Therapeutics Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co (XKRX:115450) Business Description

Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines